A-769662
A-769662是一种有效的，可逆的AMPK激活剂，在无细胞试验中EC50为0.8 μM，对GPPase/FBPase活性几乎没有作用。
A-769662 Chemical Structure
CAS: 844499-71-4
产品质控
批次：
纯度：
99.67%
99.67
A-769662相关产品
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| HeLa | Function assay | 100 uM | 1 hr | Effect on AMPK activation in HeLa cells at 100 uM after 1 hr by immunoprecipitate kinase assay | 17855357 |
| HeLa | Function assay | 100 uM | 1 hr | Effect on AMPK phosphorylation in HeLa cells at 100 uM after 1 hr by immunoprecipitate kinase assay | 17855357 |
| HeLa | Function assay | 100 uM | 5 mins | Effect on AMPK phosphorylation in HeLa cells at 100 uM after 5 mins by immunoprecipitate kinase assay | 17855357 |
| HeLa | Function assay | 100 uM | 1 hr | Effect on acetyl-CoA carboxylase phosphorylation in HeLa cells at 100 uM after 1 hr by densitometry | 17855357 |
| HeLa | Function assay | 100 uM | 1 hr | Reduction of AMPK phosphorylation in HeLa cells at 100 uM after 1 hr in presence of STO-609 by immunoprecipitate kinase assay | 17855357 |
| HeLa | Function assay | 100 uM | 1 hr | Reduction of AMPK activation in HeLa cells at 100 uM after 1 hr in presence of STO-609 by immunoprecipitate kinase assay | 17855357 |
| HeLa | Function assay | 100 uM | 1 hr | Reduction of acetyl-CoA carboxylase phosphorylation in HeLa cells at 100 uM after 1 hr in presence of STO-609 by densitometry | 17855357 |
| MG-63 | cytotoxicity assay | 10 µM | inhibits H2O2-Induced Osteoblast Cell Death | 24960362 | |
| Mesenchymal stem cells | cytotoxicity assay | 100 µM | decreases the MSC proliferation | 24104879 | |
| Mesenchymal stem cells | Kinase assay | 10 µM | induces a robust and sustained AMPK activation | 24104879 | |
| MCF7 | Apoptosis assay | 400 μM | sensitizes human breast cancer cell lines to TRAIL-induced apoptosis | 19896469 | |
| BT474 | Apoptosis assay | 400 μM | sensitizes human breast cancer cell lines to TRAIL-induced apoptosis | 19896469 | |
| MDA-MB231 | Apoptosis assay | 400 μM | sensitizes human breast cancer cell lines to TRAIL-induced apoptosis | 19896469 | |
| L6 skeletal muscle cells | Function assay | 250 μM | inhibits the Na+-K+-ATPase transport activity and cell surface abundance | 19828836 | |
| L6 skeletal muscle cells | Function assay | 250 μM | activates AMPK signaling pathways | 19828836 | |
| 3T3-L1 | Kinase assay | 1.2 mM | activates AMPK | 19483304 | |
| 3T3-L1 | cytotoxicity assay | 1.2 mM | decreases Cell Viability | 19483304 | |
| 3T3-L1 | Function assay | 1.2 mM | inhibits Mitotic Clonal Expansion | 19483304 | |
| 3T3-L1 | Function assay | 1.2 mM | inhibits the Expression of AdipogenesisRelated Transcription Factors and Markers | 19483304 | |
| 3T3-L1 | Function assay | 1.2 mM | inhibits 3T3-L1 Adipogenesis | 19483304 | |
| epididymal clear cells | Function assay | 200 μM | inhibits the pH-mediated V-ATPase accumulation at the apical membrane | 19211918 | |
| MEFs | Function assay | 300 μM | inhibits proteasomal function by an AMPK-independent mechanism | 18593584 | |
| CCL13 | Kinase assay | 200 μM | activates endogenous AMPK | 17728241 | |
| HEK293 | Kinase assay | 200 μM | activates endogenous AMPK | 17728241 | |
| rat hepatocytes | Function assay | 1 mM | inhibits fatty acid synthesis with IC50 of 3.6 μM | 16753576 | |
| mouse hepatocytes | Function assay | 1 mM | inhibits fatty acid synthesis with IC50 of 3.6 μM | 16753576 | |
| MC3T3-E1 | cytotoxicity assay | 10 µM | inhibits H2O2-Induced Osteoblast Cell Death | 24960362 | |
| MG-63 | Apoptosis assay | 10 µM | suppresses H2O2-Induced Osteoblast Cell Apoptosis | 24960362 | |
| MC3T3-E1 | Apoptosis assay | 10 µM | suppresses H2O2-Induced Osteoblast Cell Apoptosis | 24960362 | |
| MG-63 | Function assay | 10 µM | alleviates ROS accumulation and ATP depletion caused by H2O2 | 24960362 | |
| MC3T3-E1 | Function assay | 10 µM | alleviates ROS accumulation and ATP depletion caused by H2O2 | 24960362 | |
| MG-63 | Function assay | 10 µM | facilitates H2O2-induced autophagy activation | 24960362 | |
| MC3T3-E1 | Function assay | 10 µM | facilitates H2O2-induced autophagy activation | 24960362 | |
| PC3 | Kinase assay | 100 µM | upregulates the levels of AMPK and ACC phosphorylation | 25594043 | |
| PC3M | Kinase assay | 100 µM | upregulates the levels of AMPK and ACC phosphorylation | 25594043 | |
| PC3 | Function assay | 100 µM | induces PI3K/mTOR pathways | 25594043 | |
| PC3M | Function assay | 100 µM | induces PI3K/mTOR pathways | 25594043 | |
| PC3 | Growth inhibitory assay | 100 µM | suppresses proliferation | 25594043 | |
| PC3M | Growth inhibitory assay | 100 µM | suppresses proliferation | 25594043 | |
| MC3T3-E1 | Kinase assay | 10 μM | induces significant AMPK activation | 26891866 | |
| MC3T3-E1 | Growth inhibitory assay | 10 μM | inhibits Dex-induced osteoblast cell death | 26891866 | |
| MC3T3-E1 | Function assay | 10 μM | inhibits Dex-induced oxidative stress | 26891866 | |
| BL21 | Function assay | 1 to 10 mins | Binding affinity to human recombinant N-terminal AVI-tagged phosphorylated AMPK alpha1beta1gamma1 expressed in Escherichia coli BL21 cells after 1 to 10 mins by biolayer interferometry, Kd = 0.51 μM. | 26510622 | |
| BL21 | Function assay | 1 to 10 mins | Binding affinity to human recombinant N-terminal AVI-tagged phosphorylated AMPK alpha1beta2gamma1 expressed in Escherichia coli BL21 cells after 1 to 10 mins by biolayer interferometry, Kd = 14.5 μM. | 26510622 | |
| CMK | Growth Inhibition Assay | Inhibition of human CMK cell growth in a cell viability assay, IC50 = 0.002202 μM. | SANGER | ||
| SIG-M5 | Growth Inhibition Assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50 = 0.007856 μM. | SANGER | ||
| MV-4-11 | Growth Inhibition Assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 0.02274 μM. | SANGER | ||
| GDM-1 | Growth Inhibition Assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50 = 0.02553 μM. | SANGER | ||
| A431 | Growth Inhibition Assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 0.02919 μM. | SANGER | ||
| NALM-6 | Growth Inhibition Assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50 = 0.03166 μM. | SANGER | ||
| KM12 | Growth Inhibition Assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 0.03213 μM. | SANGER | ||
| QIMR-WIL | Growth Inhibition Assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50 = 0.03642 μM. | SANGER | ||
| NH-12 | Growth Inhibition Assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 0.03689 μM. | SANGER | ||
| KASUMI-1 | Growth Inhibition Assay | Inhibition of human KASUMI-1 cell growth in a cell viability assay, IC50 = 0.0418 μM. | SANGER | ||
| ML-2 | Growth Inhibition Assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 0.04344 μM. | SANGER | ||
| YT | Growth Inhibition Assay | Inhibition of human YT cell growth in a cell viability assay, IC50 = 0.0467 μM. | SANGER | ||
| Daudi | Growth Inhibition Assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50 = 0.04979 μM. | SANGER | ||
| OCI-AML2 | Growth Inhibition Assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 0.0572 μM. | SANGER | ||
| ALL-PO | Growth Inhibition Assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50 = 0.05793 μM. | SANGER | ||
| MOLT-16 | Growth Inhibition Assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 0.06191 μM. | SANGER | ||
| EHEB | Growth Inhibition Assay | Inhibition of human EHEB cell growth in a cell viability assay, IC50 = 0.06325 μM. | SANGER | ||
| AM-38 | Growth Inhibition Assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50 = 0.0644 μM. | SANGER | ||
| C8166 | Growth Inhibition Assay | Inhibition of human C8166 cell growth in a cell viability assay, IC50 = 0.06619 μM. | SANGER | ||
| RPMI-6666 | Growth Inhibition Assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50 = 0.06798 μM. | SANGER | ||
| BC-1 | Growth Inhibition Assay | Inhibition of human BC-1 cell growth in a cell viability assay, IC50 = 0.06973 μM. | SANGER | ||
| CTV-1 | Growth Inhibition Assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 0.07303 μM. | SANGER | ||
| HC-1 | Growth Inhibition Assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50 = 0.08314 μM. | SANGER | ||
| JiyoyeP-2003 | Growth Inhibition Assay | Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50 = 0.08371 μM. | SANGER | ||
| RS4-11 | Growth Inhibition Assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 0.08572 μM. | SANGER | ||
| PF-382 | Growth Inhibition Assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50 = 0.0859 μM. | SANGER | ||
| G-361 | Growth Inhibition Assay | Inhibition of human G-361 cell growth in a cell viability assay, IC50 = 0.08815 μM. | SANGER | ||
| LOXIMVI | Growth Inhibition Assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 0.08833 μM. | SANGER | ||
| A3-KAW | Growth Inhibition Assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 0.09169 μM. | SANGER | ||
| EoL-1-cell | Growth Inhibition Assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50 = 0.09558 μM. | SANGER | ||
| LOUCY | Growth Inhibition Assay | Inhibition of human LOUCY cell growth in a cell viability assay, IC50 = 0.09641 μM. | SANGER | ||
| HL-60 | Growth Inhibition Assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 0.09739 μM. | SANGER | ||
| MC116 | Growth Inhibition Assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50 = 0.10014 μM. | SANGER | ||
| CESS | Growth Inhibition Assay | Inhibition of human CESS cell growth in a cell viability assay, IC50 = 0.1011 μM. | SANGER | ||
| REH | Growth Inhibition Assay | Inhibition of human REH cell growth in a cell viability assay, IC50 = 0.10382 μM. | SANGER | ||
| HCC2157 | Growth Inhibition Assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50 = 0.10455 μM. | SANGER | ||
| HEL | Growth Inhibition Assay | Inhibition of human HEL cell growth in a cell viability assay, IC50 = 0.10728 μM. | SANGER | ||
| BL-70 | Growth Inhibition Assay | Inhibition of human BL-70 cell growth in a cell viability assay, IC50 = 0.10805 μM. | SANGER | ||
| NCI-H1770 | Growth Inhibition Assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50 = 0.10865 μM. | SANGER | ||
| SK-MM-2 | Growth Inhibition Assay | Inhibition of human SK-MM-2 cell growth in a cell viability assay, IC50 = 0.10944 μM. | SANGER | ||
| MONO-MAC-6 | Growth Inhibition Assay | Inhibition of human MONO-MAC-6 cell growth in a cell viability assay, IC50 = 0.11372 μM. | SANGER | ||
| SR | Growth Inhibition Assay | Inhibition of human SR cell growth in a cell viability assay, IC50 = 0.11387 μM. | SANGER | ||
| MOLT-4 | Growth Inhibition Assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 0.11446 μM. | SANGER | ||
| KE-37 | Growth Inhibition Assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50 = 0.12924 μM. | SANGER | ||
| ST486 | Growth Inhibition Assay | Inhibition of human ST486 cell growth in a cell viability assay, IC50 = 0.13527 μM. | SANGER | ||
| HDLM-2 | Growth Inhibition Assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50 = 0.13616 μM. | SANGER | ||
| ARH-77 | Growth Inhibition Assay | Inhibition of human ARH-77 cell growth in a cell viability assay, IC50 = 0.1406 μM. | SANGER | ||
| EB2 | Growth Inhibition Assay | Inhibition of human EB2 cell growth in a cell viability assay, IC50 = 0.14234 μM. | SANGER | ||
| CCRF-CEM | Growth Inhibition Assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50 = 0.14576 μM. | SANGER | ||
| HD-MY-Z | Growth Inhibition Assay | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50 = 0.14791 μM. | SANGER | ||
| BT-474 | Growth Inhibition Assay | Inhibition of human BT-474 cell growth in a cell viability assay, IC50 = 0.15074 μM. | SANGER | ||
| KARPAS-45 | Growth Inhibition Assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 0.16984 μM. | SANGER | ||
| Ramos-2G6-4C10 | Growth Inhibition Assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 0.1715 μM. | SANGER | ||
| MC-CAR | Growth Inhibition Assay | Inhibition of human MC-CAR cell growth in a cell viability assay, IC50 = 0.17153 μM. | SANGER | ||
| MRK-nu-1 | Growth Inhibition Assay | Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50 = 0.17751 μM. | SANGER | ||
| MHH-PREB-1 | Growth Inhibition Assay | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50 = 0.18242 μM. | SANGER | ||
| SK-NEP-1 | Growth Inhibition Assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 0.18514 μM. | SANGER | ||
| BL-41 | Growth Inhibition Assay | Inhibition of human BL-41 cell growth in a cell viability assay, IC50 = 0.18943 μM. | SANGER | ||
| CAS-1 | Growth Inhibition Assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50 = 0.19307 μM. | SANGER | ||
| NCI-H1522 | Growth Inhibition Assay | Inhibition of human NCI-H1522 cell growth in a cell viability assay, IC50 = 0.19355 μM. | SANGER | ||
| CA46 | Growth Inhibition Assay | Inhibition of human CA46 cell growth in a cell viability assay, IC50 = 0.19556 μM. | SANGER | ||
| L-363 | Growth Inhibition Assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 0.21121 μM. | SANGER | ||
| NCI-H2087 | Growth Inhibition Assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 0.21446 μM. | SANGER | ||
| GR-ST | Growth Inhibition Assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 0.21764 μM. | SANGER | ||
| OPM-2 | Growth Inhibition Assay | Inhibition of human OPM-2 cell growth in a cell viability assay, IC50 = 0.21791 μM. | SANGER | ||
| U-698-M | Growth Inhibition Assay | Inhibition of human U-698-M cell growth in a cell viability assay, IC50 = 0.21915 μM. | SANGER | ||
| CAL-148 | Growth Inhibition Assay | Inhibition of human CAL-148 cell growth in a cell viability assay, IC50 = 0.22342 μM. | SANGER | ||
| L-428 | Growth Inhibition Assay | Inhibition of human L-428 cell growth in a cell viability assay, IC50 = 0.22499 μM. | SANGER | ||
| DEL | Growth Inhibition Assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 0.22825 μM. | SANGER | ||
| LU-134-A | Growth Inhibition Assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50 = 0.23116 μM. | SANGER | ||
| MLMA | Growth Inhibition Assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50 = 0.23399 μM. | SANGER | ||
| DOHH-2 | Growth Inhibition Assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50 = 0.24513 μM. | SANGER | ||
| RPMI-8226 | Growth Inhibition Assay | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50 = 0.24596 μM. | SANGER | ||
| NCI-H2196 | Growth Inhibition Assay | Inhibition of human NCI-H2196 cell growth in a cell viability assay, IC50 = 0.24776 μM. | SANGER | ||
| COR-L279 | Growth Inhibition Assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50 = 0.25293 μM. | SANGER | ||
| CAPAN-1 | Growth Inhibition Assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50 = 0.25589 μM. | SANGER | ||
| NOMO-1 | Growth Inhibition Assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 0.26322 μM. | SANGER | ||
| SUP-T1 | Growth Inhibition Assay | Inhibition of human SUP-T1 cell growth in a cell viability assay, IC50 = 0.26516 μM. | SANGER | ||
| MEG-01 | Growth Inhibition Assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 0.2687 μM. | SANGER | ||
| CHP-126 | Growth Inhibition Assay | Inhibition of human CHP-126 cell growth in a cell viability assay, IC50 = 0.26909 μM. | SANGER | ||
| HCC1599 | Growth Inhibition Assay | Inhibition of human HCC1599 cell growth in a cell viability assay, IC50 = 0.27841 μM. | SANGER | ||
| EB-3 | Growth Inhibition Assay | Inhibition of human EB-3 cell growth in a cell viability assay, IC50 = 0.29293 μM. | SANGER | ||
| WSU-NHL | Growth Inhibition Assay | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50 = 0.29672 μM. | SANGER | ||
| COLO-684 | Growth Inhibition Assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 0.3025 μM. | SANGER | ||
| LAMA-84 | Growth Inhibition Assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 0.30816 μM. | SANGER | ||
| TGW | Growth Inhibition Assay | Inhibition of human TGW cell growth in a cell viability assay, IC50 = 0.31095 μM. | SANGER | ||
| NCI-SNU-1 | Growth Inhibition Assay | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50 = 0.31106 μM. | SANGER | ||
| MHH-NB-11 | Growth Inhibition Assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 0.32291 μM. | SANGER | ||
| COLO-824 | Growth Inhibition Assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50 = 0.32838 μM. | SANGER | ||
| U-87-MG | Growth Inhibition Assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50 = 0.33314 μM. | SANGER | ||
| HT | Growth Inhibition Assay | Inhibition of human HT cell growth in a cell viability assay, IC50 = 0.33482 μM. | SANGER | ||
| THP-1 | Growth Inhibition Assay | Inhibition of human THP-1 cell growth in a cell viability assay, IC50 = 0.34164 μM. | SANGER | ||
| HCC2218 | Growth Inhibition Assay | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50 = 0.3418 μM. | SANGER | ||
| KARPAS-422 | Growth Inhibition Assay | Inhibition of human KARPAS-422 cell growth in a cell viability assay, IC50 = 0.34433 μM. | SANGER | ||
| EM-2 | Growth Inhibition Assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 0.34443 μM. | SANGER | ||
| TUR | Growth Inhibition Assay | Inhibition of human TUR cell growth in a cell viability assay, IC50 = 0.34453 μM. | SANGER | ||
| MN-60 | Growth Inhibition Assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 0.34596 μM. | SANGER | ||
| DMS-153 | Growth Inhibition Assay | Inhibition of human DMS-153 cell growth in a cell viability assay, IC50 = 0.37276 μM. | SANGER | ||
| J-RT3-T3-5 | Growth Inhibition Assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 0.37831 μM. | SANGER | ||
| EVSA-T | Growth Inhibition Assay | Inhibition of human EVSA-T cell growth in a cell viability assay, IC50 = 0.38095 μM. | SANGER | ||
| SHP-77 | Growth Inhibition Assay | Inhibition of human SHP-77 cell growth in a cell viability assay, IC50 = 0.38298 μM. | SANGER | ||
| D-283MED | Growth Inhibition Assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50 = 0.38569 μM. | SANGER | ||
| GOTO | Growth Inhibition Assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50 = 0.39536 μM. | SANGER | ||
| KMOE-2 | Growth Inhibition Assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50 = 0.39664 μM. | SANGER | ||
| U-266 | Growth Inhibition Assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 0.40452 μM. | SANGER | ||
| NCI-H226 | Growth Inhibition Assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 0.40703 μM. | SANGER | ||
| KG-1 | Growth Inhibition Assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 0.40876 μM. | SANGER | ||
| NCI-H1882 | Growth Inhibition Assay | Inhibition of human NCI-H1882 cell growth in a cell viability assay, IC50 = 0.40912 μM. | SANGER | ||
| KMS-12-PE | Growth Inhibition Assay | Inhibition of human KMS-12-PE cell growth in a cell viability assay, IC50 = 0.41877 μM. | SANGER | ||
| KM-H2 | Growth Inhibition Assay | Inhibition of human KM-H2 cell growth in a cell viability assay, IC50 = 0.42374 μM. | SANGER | ||
| NCI-H1417 | Growth Inhibition Assay | Inhibition of human NCI-H1417 cell growth in a cell viability assay, IC50 = 0.43916 μM. | SANGER | ||
| RPMI-8402 | Growth Inhibition Assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50 = 0.44161 μM. | SANGER | ||
| EW-18 | Growth Inhibition Assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50 = 0.45104 μM. | SANGER | ||
| HH | Growth Inhibition Assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 0.45751 μM. | SANGER | ||
| NCI-H526 | Growth Inhibition Assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 0.46847 μM. | SANGER | ||
| NEC8 | Growth Inhibition Assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50 = 0.48029 μM. | SANGER | ||
| P12-ICHIKAWA | Growth Inhibition Assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50 = 0.48862 μM. | SANGER | ||
| DB | Growth Inhibition Assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 0.48893 μM. | SANGER | ||
| SJRH30 | Growth Inhibition Assay | Inhibition of human SJRH30 cell growth in a cell viability assay, IC50 = 0.49478 μM. | SANGER | ||
| ATN-1 | Growth Inhibition Assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50 = 0.49906 μM. | SANGER | ||
| ECC4 | Growth Inhibition Assay | Inhibition of human ECC4 cell growth in a cell viability assay, IC50 = 0.50901 μM. | SANGER | ||
| LU-65 | Growth Inhibition Assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50 = 0.52007 μM. | SANGER | ||
| NCI-H1092 | Growth Inhibition Assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 0.54078 μM. | SANGER | ||
| NCI-H187 | Growth Inhibition Assay | Inhibition of human NCI-H187 cell growth in a cell viability assay, IC50 = 0.54464 μM. | SANGER | ||
| LNCaP-Clone-FGC | Growth Inhibition Assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50 = 0.5472 μM. | SANGER | ||
| LC4-1 | Growth Inhibition Assay | Inhibition of human LC4-1 cell growth in a cell viability assay, IC50 = 0.56308 μM. | SANGER | ||
| NCI-H1436 | Growth Inhibition Assay | Inhibition of human NCI-H1436 cell growth in a cell viability assay, IC50 = 0.59043 μM. | SANGER | ||
| NCI-H2171 | Growth Inhibition Assay | Inhibition of human NCI-H2171 cell growth in a cell viability assay, IC50 = 0.62179 μM. | SANGER | ||
| LB647-SCLC | Growth Inhibition Assay | Inhibition of human LB647-SCLC cell growth in a cell viability assay, IC50 = 0.62241 μM. | SANGER | ||
| NCI-H2141 | Growth Inhibition Assay | Inhibition of human NCI-H2141 cell growth in a cell viability assay, IC50 = 0.63266 μM. | SANGER | ||
| NCI-H1304 | Growth Inhibition Assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50 = 0.63388 μM. | SANGER | ||
| Raji | Growth Inhibition Assay | Inhibition of human Raji cell growth in a cell viability assay, IC50 = 0.66976 μM. | SANGER | ||
| NB69 | Growth Inhibition Assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 0.68575 μM. | SANGER | ||
| NCI-H510A | Growth Inhibition Assay | Inhibition of human NCI-H510A cell growth in a cell viability assay, IC50 = 0.69172 μM. | SANGER | ||
| COR-L88 | Growth Inhibition Assay | Inhibition of human COR-L88 cell growth in a cell viability assay, IC50 = 0.72456 μM. | SANGER | ||
| K052 | Growth Inhibition Assay | Inhibition of human K052 cell growth in a cell viability assay, IC50 = 0.79127 μM. | SANGER | ||
| SK-N-DZ | Growth Inhibition Assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50 = 0.80231 μM. | SANGER | ||
| KY821 | Growth Inhibition Assay | Inhibition of human KY821 cell growth in a cell viability assay, IC50 = 0.81743 μM. | SANGER | ||
| MDA-MB-157 | Growth Inhibition Assay | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50 = 0.82406 μM. | SANGER | ||
| MS-1 | Growth Inhibition Assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 0.82745 μM. | SANGER | ||
| L-540 | Growth Inhibition Assay | Inhibition of human L-540 cell growth in a cell viability assay, IC50 = 0.84843 μM. | SANGER | ||
| MDA-MB-361 | Growth Inhibition Assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 0.86048 μM. | SANGER | ||
| NCI-SNU-5 | Growth Inhibition Assay | Inhibition of human NCI-SNU-5 cell growth in a cell viability assay, IC50 = 0.94375 μM. | SANGER | ||
| KARPAS-299 | Growth Inhibition Assay | Inhibition of human KARPAS-299 cell growth in a cell viability assay, IC50 = 0.94828 μM. | SANGER | ||
| NCI-H1694 | Growth Inhibition Assay | Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50 = 0.9773 μM. | SANGER | ||
| P30-OHK | Growth Inhibition Assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 0.99292 μM. | SANGER | ||
| LU-165 | Growth Inhibition Assay | Inhibition of human LU-165 cell growth in a cell viability assay, IC50 = 1.05606 μM. | SANGER | ||
| NB1 | Growth Inhibition Assay | Inhibition of human NB1 cell growth in a cell viability assay, IC50 = 1.11241 μM. | SANGER | ||
| UACC-812 | Growth Inhibition Assay | Inhibition of human UACC-812 cell growth in a cell viability assay, IC50 = 1.1488 μM. | SANGER | ||
| RL | Growth Inhibition Assay | Inhibition of human RL cell growth in a cell viability assay, IC50 = 1.16282 μM. | SANGER | ||
| NCI-H69 | Growth Inhibition Assay | Inhibition of human NCI-H69 cell growth in a cell viability assay, IC50 = 1.19391 μM. | SANGER | ||
| SW1417 | Growth Inhibition Assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 1.23671 μM. | SANGER | ||
| NCI-H1155 | Growth Inhibition Assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50 = 1.27588 μM. | SANGER | ||
| NCI-H1581 | Growth Inhibition Assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50 = 1.44028 μM. | SANGER | ||
| MHH-CALL-2 | Growth Inhibition Assay | Inhibition of human MHH-CALL-2 cell growth in a cell viability assay, IC50 = 1.48514 μM. | SANGER | ||
| SCLC-21H | Growth Inhibition Assay | Inhibition of human SCLC-21H cell growth in a cell viability assay, IC50 = 1.67837 μM. | SANGER | ||
| LK-2 | Growth Inhibition Assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50 = 1.71089 μM. | SANGER | ||
| CPC-N | Growth Inhibition Assay | Inhibition of human CPC-N cell growth in a cell viability assay, IC50 = 1.76764 μM. | SANGER | ||
| SCC-3 | Growth Inhibition Assay | Inhibition of human SCC-3 cell growth in a cell viability assay, IC50 = 2.04311 μM. | SANGER | ||
| NCI-H446 | Growth Inhibition Assay | Inhibition of human NCI-H446 cell growth in a cell viability assay, IC50 = 2.05293 μM. | SANGER | ||
| RH-1 | Growth Inhibition Assay | Inhibition of human RH-1 cell growth in a cell viability assay, IC50 = 2.13933 μM. | SANGER | ||
| NCI-H345 | Growth Inhibition Assay | Inhibition of human NCI-H345 cell growth in a cell viability assay, IC50 = 2.14996 μM. | SANGER | ||
| A253 | Growth Inhibition Assay | Inhibition of human A253 cell growth in a cell viability assay, IC50 = 2.25377 μM. | SANGER | ||
| DMS-79 | Growth Inhibition Assay | Inhibition of human DMS-79 cell growth in a cell viability assay, IC50 = 2.36386 μM. | SANGER | ||
| SK-N-FI | Growth Inhibition Assay | Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50 = 2.50034 μM. | SANGER | ||
| SK-MEL-1 | Growth Inhibition Assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50 = 2.61066 μM. | SANGER | ||
| HuO-3N1 | Growth Inhibition Assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50 = 2.69128 μM. | SANGER | ||
| SIMA | Growth Inhibition Assay | Inhibition of human SIMA cell growth in a cell viability assay, IC50 = 2.72143 μM. | SANGER | ||
| SU-DHL-1 | Growth Inhibition Assay | Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50 = 2.90246 μM. | SANGER | ||
| P31-FUJ | Growth Inhibition Assay | Inhibition of human P31-FUJ cell growth in a cell viability assay, IC50 = 3.01209 μM. | SANGER | ||
| A101D | Growth Inhibition Assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 3.23245 μM. | SANGER | ||
| RPMI-8866 | Growth Inhibition Assay | Inhibition of human RPMI-8866 cell growth in a cell viability assay, IC50 = 3.58797 μM. | SANGER | ||
| NCI-H209 | Growth Inhibition Assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50 = 3.59247 μM. | SANGER | ||
| JVM-2 | Growth Inhibition Assay | Inhibition of human JVM-2 cell growth in a cell viability assay, IC50 = 3.62244 μM. | SANGER | ||
| LP-1 | Growth Inhibition Assay | Inhibition of human LP-1 cell growth in a cell viability assay, IC50 = 3.79042 μM. | SANGER | ||
| IST-SL1 | Growth Inhibition Assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50 = 3.91611 μM. | SANGER | ||
| TE-9 | Growth Inhibition Assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50 = 3.99619 μM. | SANGER | ||
| NCI-H1618 | Growth Inhibition Assay | Inhibition of human NCI-H1618 cell growth in a cell viability assay, IC50 = 4.17788 μM. | SANGER | ||
| COR-L105 | Growth Inhibition Assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 4.51462 μM. | SANGER | ||
| KU-19-19 | Growth Inhibition Assay | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50 = 4.56729 μM. | SANGER | ||
| HCC70 | Growth Inhibition Assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 5.75167 μM. | SANGER | ||
| DG-75 | Growth Inhibition Assay | Inhibition of human DG-75 cell growth in a cell viability assay, IC50 = 6.18885 μM. | SANGER | ||
| CCF-STTG1 | Growth Inhibition Assay | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50 = 6.74902 μM. | SANGER | ||
| SBC-1 | Growth Inhibition Assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50 = 6.88808 μM. | SANGER | ||
| CAL-85-1 | Growth Inhibition Assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50 = 7.45587 μM. | SANGER | ||
| BxPC-3 | Growth Inhibition Assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 7.56085 μM. | SANGER | ||
| YAPC | Growth Inhibition Assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 7.74286 μM. | SANGER | ||
| HCC1806 | Growth Inhibition Assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50 = 8.04507 μM. | SANGER | ||
| SK-MEL-28 | Growth Inhibition Assay | Inhibition of human SK-MEL-28 cell growth in a cell viability assay, IC50 = 8.42441 μM. | SANGER | ||
| Ca9-22 | Growth Inhibition Assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 8.62748 μM. | SANGER | ||
| NCI-H889 | Growth Inhibition Assay | Inhibition of human NCI-H889 cell growth in a cell viability assay, IC50 = 9.42457 μM. | SANGER | ||
| HT-3 | Growth Inhibition Assay | Inhibition of human HT-3 cell growth in a cell viability assay, IC50 = 9.4754 μM. | SANGER | ||
| H4 | Growth Inhibition Assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 9.59864 μM. | SANGER | ||
| NCI-H2228 | Growth Inhibition Assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 9.87581 μM. | SANGER | ||
| M14 | Growth Inhibition Assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 10.5224 μM. | SANGER | ||
| OVCAR-3 | Growth Inhibition Assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50 = 11.4748 μM. | SANGER | ||
| HCC1187 | Growth Inhibition Assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50 = 11.4776 μM. | SANGER | ||
| RT4 | Growth Inhibition Assay | Inhibition of human RT4 cell growth in a cell viability assay, IC50 = 11.6532 μM. | SANGER | ||
| SW962 | Growth Inhibition Assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 12.004 μM. | SANGER | ||
| BB49-HNC | Growth Inhibition Assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 12.0436 μM. | SANGER | ||
| HCE-4 | Growth Inhibition Assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50 = 12.7585 μM. | SANGER | ||
| KU812 | Growth Inhibition Assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50 = 13.9562 μM. | SANGER | ||
| JAR | Growth Inhibition Assay | Inhibition of human JAR cell growth in a cell viability assay, IC50 = 14.113 μM. | SANGER | ||
| NCI-H2009 | Growth Inhibition Assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50 = 14.287 μM. | SANGER | ||
| HuO9 | Growth Inhibition Assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50 = 14.4446 μM. | SANGER | ||
| U-118-MG | Growth Inhibition Assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 14.5013 μM. | SANGER | ||
| SH-4 | Growth Inhibition Assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 14.942 μM. | SANGER | ||
| ES5 | Growth Inhibition Assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50 = 15.3528 μM. | SANGER | ||
| NB6 | Growth Inhibition Assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50 = 15.4452 μM. | SANGER | ||
| COLO-829 | Growth Inhibition Assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50 = 15.6978 μM. | SANGER | ||
| NCI-H524 | Growth Inhibition Assay | Inhibition of human NCI-H524 cell growth in a cell viability assay, IC50 = 15.751 μM. | SANGER | ||
| HPAF-II | Growth Inhibition Assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 16.1017 μM. | SANGER | ||
| GB-1 | Growth Inhibition Assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 16.5577 μM. | SANGER | ||
| LB771-HNC | Growth Inhibition Assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50 = 16.8228 μM. | SANGER | ||
| HuCCT1 | Growth Inhibition Assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 17.176 μM. | SANGER | ||
| SW837 | Growth Inhibition Assay | Inhibition of human SW837 cell growth in a cell viability assay, IC50 = 17.3011 μM. | SANGER | ||
| NCI-N87 | Growth Inhibition Assay | Inhibition of human NCI-N87 cell growth in a cell viability assay, IC50 = 17.5302 μM. | SANGER | ||
| BEN | Growth Inhibition Assay | Inhibition of human BEN cell growth in a cell viability assay, IC50 = 17.7386 μM. | SANGER | ||
| Mewo | Growth Inhibition Assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 17.8382 μM. | SANGER | ||
| MPP-89 | Growth Inhibition Assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50 = 18.2784 μM. | SANGER | ||
| NOS-1 | Growth Inhibition Assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50 = 18.3793 μM. | SANGER | ||
| Ca-Ski | Growth Inhibition Assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50 = 19.7889 μM. | SANGER | ||
| SW1088 | Growth Inhibition Assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50 = 19.9447 μM. | SANGER | ||
| Capan-2 | Growth Inhibition Assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 20.3327 μM. | SANGER | ||
| A498 | Growth Inhibition Assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 20.4092 μM. | SANGER | ||
| COLO-800 | Growth Inhibition Assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50 = 20.9232 μM. | SANGER | ||
| OVCAR-4 | Growth Inhibition Assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 21.2508 μM. | SANGER | ||
| K-562 | Growth Inhibition Assay | Inhibition of human K-562 cell growth in a cell viability assay, IC50 = 21.9049 μM. | SANGER | ||
| IA-LM | Growth Inhibition Assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50 = 22.3771 μM. | SANGER | ||
| SK-LMS-1 | Growth Inhibition Assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50 = 22.4057 μM. | SANGER | ||
| CAL-51 | Growth Inhibition Assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50 = 23.0872 μM. | SANGER | ||
| NCI-H1651 | Growth Inhibition Assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 24.1303 μM. | SANGER | ||
| GMS-10 | Growth Inhibition Assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 24.4376 μM. | SANGER | ||
| NCI-H2347 | Growth Inhibition Assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 24.6005 μM. | SANGER | ||
| MEL-JUSO | Growth Inhibition Assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50 = 24.6906 μM. | SANGER | ||
| SW948 | Growth Inhibition Assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 24.9296 μM. | SANGER | ||
| MKN45 | Growth Inhibition Assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50 = 26.4465 μM. | SANGER | ||
| HCC1954 | Growth Inhibition Assay | Inhibition of human HCC1954 cell growth in a cell viability assay, IC50 = 26.4502 μM. | SANGER | ||
| SAS | Growth Inhibition Assay | Inhibition of human SAS cell growth in a cell viability assay, IC50 = 26.4732 μM. | SANGER | ||
| SCC-25 | Growth Inhibition Assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 26.5693 μM. | SANGER | ||
| MKN28 | Growth Inhibition Assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50 = 26.7093 μM. | SANGER | ||
| T84 | Growth Inhibition Assay | Inhibition of human T84 cell growth in a cell viability assay, IC50 = 26.7743 μM. | SANGER | ||
| HCT-15 | Growth Inhibition Assay | Inhibition of human HCT-15 cell growth in a cell viability assay, IC50 = 26.9389 μM. | SANGER | ||
| DOK | Growth Inhibition Assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 27.0723 μM. | SANGER | ||
| SK-MEL-24 | Growth Inhibition Assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50 = 28.0766 μM. | SANGER | ||
| HCC1143 | Growth Inhibition Assay | Inhibition of human HCC1143 cell growth in a cell viability assay, IC50 = 28.2552 μM. | SANGER | ||
| JEG-3 | Growth Inhibition Assay | Inhibition of human JEG-3 cell growth in a cell viability assay, IC50 = 28.4578 μM. | SANGER | ||
| SF539 | Growth Inhibition Assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 28.6049 μM. | SANGER | ||
| NB12 | Growth Inhibition Assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50 = 28.8033 μM. | SANGER | ||
| Hs-578-T | Growth Inhibition Assay | Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50 = 29.1197 μM. | SANGER | ||
| HCT-116 | Growth Inhibition Assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 29.4423 μM. | SANGER | ||
| EW-3 | Growth Inhibition Assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50 = 29.5269 μM. | SANGER | ||
| 639-V | Growth Inhibition Assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 29.8546 μM. | SANGER | ||
| IGR-1 | Growth Inhibition Assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 30.0191 μM. | SANGER | ||
| LS-411N | Growth Inhibition Assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 30.351 μM. | SANGER | ||
| D-502MG | Growth Inhibition Assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50 = 30.3725 μM. | SANGER | ||
| AN3-CA | Growth Inhibition Assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 31.4329 μM. | SANGER | ||
| RCC10RGB | Growth Inhibition Assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 31.4464 μM. | SANGER | ||
| GT3TKB | Growth Inhibition Assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 31.7096 μM. | SANGER | ||
| BB30-HNC | Growth Inhibition Assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50 = 32.5217 μM. | SANGER | ||
| HT-144 | Growth Inhibition Assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 32.7065 μM. | SANGER | ||
| NCI-H1355 | Growth Inhibition Assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 33.3495 μM. | SANGER | ||
| D-542MG | Growth Inhibition Assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50 = 33.3722 μM. | SANGER | ||
| NCI-H727 | Growth Inhibition Assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50 = 33.4114 μM. | SANGER | ||
| NCI-H1755 | Growth Inhibition Assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50 = 33.5236 μM. | SANGER | ||
| KS-1 | Growth Inhibition Assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 33.6298 μM. | SANGER | ||
| SW626 | Growth Inhibition Assay | Inhibition of human SW626 cell growth in a cell viability assay, IC50 = 33.7643 μM. | SANGER | ||
| MZ1-PC | Growth Inhibition Assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 33.8103 μM. | SANGER | ||
| NCI-H1650 | Growth Inhibition Assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 34.326 μM. | SANGER | ||
| LCLC-97TM1 | Growth Inhibition Assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 34.8526 μM. | SANGER | ||
| HTC-C3 | Growth Inhibition Assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 35.022 μM. | SANGER | ||
| SNU-387 | Growth Inhibition Assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50 = 35.2684 μM. | SANGER | ||
| IM-9 | Growth Inhibition Assay | Inhibition of human IM-9 cell growth in a cell viability assay, IC50 = 35.5165 μM. | SANGER | ||
| KYSE-180 | Growth Inhibition Assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50 = 35.6521 μM. | SANGER | ||
| HuH-7 | Growth Inhibition Assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 35.6756 μM. | SANGER | ||
| CP66-MEL | Growth Inhibition Assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50 = 35.7968 μM. | SANGER | ||
| 22RV1 | Growth Inhibition Assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50 = 35.8423 μM. | SANGER | ||
| SW48 | Growth Inhibition Assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 36.2464 μM. | SANGER | ||
| COLO-205 | Growth Inhibition Assay | Inhibition of human COLO-205 cell growth in a cell viability assay, IC50 = 37.2589 μM. | SANGER | ||
| MFH-ino | Growth Inhibition Assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50 = 37.3918 μM. | SANGER | ||
| ECC12 | Growth Inhibition Assay | Inhibition of human ECC12 cell growth in a cell viability assay, IC50 = 37.7142 μM. | SANGER | ||
| CAL-72 | Growth Inhibition Assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50 = 37.7221 μM. | SANGER | ||
| KNS-42 | Growth Inhibition Assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50 = 37.8215 μM. | SANGER | ||
| U031 | Growth Inhibition Assay | Inhibition of human U031 cell growth in a cell viability assay, IC50 = 37.827 μM. | SANGER | ||
| EFE-184 | Growth Inhibition Assay | Inhibition of human EFE-184 cell growth in a cell viability assay, IC50 = 37.8863 μM. | SANGER | ||
| TCCSUP | Growth Inhibition Assay | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50 = 38.3341 μM. | SANGER | ||
| TE-11 | Growth Inhibition Assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 39.2614 μM. | SANGER | ||
| SK-MEL-3 | Growth Inhibition Assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 39.5577 μM. | SANGER | ||
| NCI-H1703 | Growth Inhibition Assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50 = 39.5618 μM. | SANGER | ||
| NCI-H748 | Growth Inhibition Assay | Inhibition of human NCI-H748 cell growth in a cell viability assay, IC50 = 39.6102 μM. | SANGER | ||
| HuP-T3 | Growth Inhibition Assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 39.8492 μM. | SANGER | ||
| GCT | Growth Inhibition Assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 40.2935 μM. | SANGER | ||
| LU-99A | Growth Inhibition Assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50 = 40.6473 μM. | SANGER | ||
| TGBC24TKB | Growth Inhibition Assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 40.7998 μM. | SANGER | ||
| NCI-H1993 | Growth Inhibition Assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50 = 41.1086 μM. | SANGER | ||
| 769-P | Growth Inhibition Assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 41.226 μM. | SANGER | ||
| NCI-H2126 | Growth Inhibition Assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50 = 41.3099 μM. | SANGER | ||
| NCI-H1563 | Growth Inhibition Assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50 = 41.353 μM. | SANGER | ||
| NCI-H82 | Growth Inhibition Assay | Inhibition of human NCI-H82 cell growth in a cell viability assay, IC50 = 41.4039 μM. | SANGER | ||
| SW1783 | Growth Inhibition Assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50 = 41.6769 μM. | SANGER | ||
| NCI-H1648 | Growth Inhibition Assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50 = 41.9392 μM. | SANGER | ||
| A388 | Growth Inhibition Assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 42.1236 μM. | SANGER | ||
| SK-MEL-30 | Growth Inhibition Assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50 = 42.3151 μM. | SANGER | ||
| EKVX | Growth Inhibition Assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50 = 42.3726 μM. | SANGER | ||
| A172 | Growth Inhibition Assay | Inhibition of human A172 cell growth in a cell viability assay, IC50 = 42.8624 μM. | SANGER | ||
| OMC-1 | Growth Inhibition Assay | Inhibition of human OMC-1 cell growth in a cell viability assay, IC50 = 42.9399 μM. | SANGER | ||
| PANC-03-27 | Growth Inhibition Assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 43.157 μM. | SANGER | ||
| NCI-H747 | Growth Inhibition Assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 43.3223 μM. | SANGER | ||
| HT55 | Growth Inhibition Assay | Inhibition of human HT55 cell growth in a cell viability assay, IC50 = 43.7863 μM. | SANGER | ||
| BV-173 | Growth Inhibition Assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50 = 43.7946 μM. | SANGER | ||
| LS-1034 | Growth Inhibition Assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50 = 43.9899 μM. | SANGER | ||
| NUGC-3 | Growth Inhibition Assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 44.0773 μM. | SANGER | ||
| IST-MEL1 | Growth Inhibition Assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 44.2633 μM. | SANGER | ||
| 8305C | Growth Inhibition Assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 44.31 μM. | SANGER | ||
| IMR-5 | Growth Inhibition Assay | Inhibition of human IMR-5 cell growth in a cell viability assay, IC50 = 44.5743 μM. | SANGER | ||
| TE-6 | Growth Inhibition Assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50 = 44.8539 μM. | SANGER | ||
| MZ2-MEL | Growth Inhibition Assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 45.0112 μM. | SANGER | ||
| RT-112 | Growth Inhibition Assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 45.4472 μM. | SANGER | ||
| SCC-9 | Growth Inhibition Assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 45.5616 μM. | SANGER | ||
| SCC-4 | Growth Inhibition Assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 45.5626 μM. | SANGER | ||
| CAL-54 | Growth Inhibition Assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 45.6635 μM. | SANGER | ||
| LoVo | Growth Inhibition Assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 45.6839 μM. | SANGER | ||
| NCI-H358 | Growth Inhibition Assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50 = 45.7286 μM. | SANGER | ||
| K5 | Growth Inhibition Assay | Inhibition of human K5 cell growth in a cell viability assay, IC50 = 46.029 μM. | SANGER | ||
| LB1047-RCC | Growth Inhibition Assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50 = 46.4256 μM. | SANGER | ||
| MES-SA | Growth Inhibition Assay | Inhibition of human MES-SA cell growth in a cell viability assay, IC50 = 46.5121 μM. | SANGER | ||
| UACC-257 | Growth Inhibition Assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 46.5175 μM. | SANGER | ||
| NCI-H2342 | Growth Inhibition Assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50 = 46.8809 μM. | SANGER | ||
| TE-15 | Growth Inhibition Assay | Inhibition of human TE-15 cell growth in a cell viability assay, IC50 = 46.8909 μM. | SANGER | ||
| SK-MES-1 | Growth Inhibition Assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 47.3821 μM. | SANGER | ||
| NCI-H322M | Growth Inhibition Assay | Inhibition of human NCI-H322M cell growth in a cell viability assay, IC50 = 47.6561 μM. | SANGER | ||
| SK-OV-3 | Growth Inhibition Assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50 = 47.7452 μM. | SANGER | ||
| PANC-08-13 | Growth Inhibition Assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50 = 47.9641 μM. | SANGER | ||
| 786-0 | Growth Inhibition Assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 48.073 μM. | SANGER | ||
| NCI-H460 | Growth Inhibition Assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50 = 48.1255 μM. | SANGER | ||
| D-336MG | Growth Inhibition Assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50 = 48.4845 μM. | SANGER | ||
| SNG-M | Growth Inhibition Assay | Inhibition of human SNG-M cell growth in a cell viability assay, IC50 = 48.6701 μM. | SANGER | ||
| SK-CO-1 | Growth Inhibition Assay | Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50 = 49.0025 μM. | SANGER | ||
| CAL-27 | Growth Inhibition Assay | Inhibition of human CAL-27 cell growth in a cell viability assay, IC50 = 49.5334 μM. | SANGER | ||
| 8505C | Growth Inhibition Assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50 = 49.5364 μM. | SANGER | ||
| MCF7 | Growth Inhibition Assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50 = 49.5865 μM. | SANGER | ||
| T47D | Growth Inhibition Assay | Inhibition of human T47D cell growth in a cell viability assay, IC50 = 49.7007 μM. | SANGER | ||
| YKG-1 | Growth Inhibition Assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 49.9412 μM. | SANGER | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | A-769662是一种有效的，可逆的AMPK激活剂，在无细胞试验中EC50为0.8 μM，对GPPase/FBPase活性几乎没有作用。 | ||||
|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | A-769662部分刺激纯化的大鼠肝脏AMPK，EC50 为0.8 μM。A-769662以剂量响应的方式激活从多种组织和物种纯化得到的AMPK，伴随不同的EC50s。A-769662的EC50s，使用从大鼠心脏，大鼠肌肉，或人胚肾细胞(HEKs)部分纯化的AMPK测定，结果分别为2.2 mM，1.9 mM，或1.1 mM。原代大鼠肝细胞用A-769662处理4小时剂量依赖性增加ACC磷酸化，其与脂肪酸合成的抑制相关，IC50为3.2 μM。A-769662也会抑制小鼠肝细胞中脂肪酸合成，IC50为3.6 μM。[1] A-769662通过变构调节和抑制AMPK在Thr-172上的去磷酸化作用激活AMPK，类似于AMP的作用。[2] A-769662通过与AMPK无关的作用机制抑制蛋白酶体功能。 A-769662影响纯化26S蛋白酶体的体外活性，但是不影响纯化20S蛋白酶体的体外活性。A-769662对MEF细胞具有毒性作用。[3]一项最近的研究表明，A-769662抑制细胞增殖和DNA合成。[4] |
|||
|---|---|---|---|---|
| 激酶实验 | 96-孔 AMPK 试验 | |||
| AMPK活性通过监测SAMS多肽底物(标准试验中为20 μM，附加试验中为100 μM)磷酸化根据前述方案(Anderson et al., 2004)测量。为测定 A-769662诱导的AMPK活化是否可逆，AMP或A-769662与大鼠肝脏AMPK在20倍标准试验浓度下预培养10分钟，然后稀释并测量AMPK活性。 | ||||
| 细胞实验 | 细胞系 | MEF细胞 | ||
| 浓度 | 300 μM | |||
| 孵育时间 | 24小时 | |||
| 方法 | A-769662处理或未处理的MEF细胞的细胞活性如下进行测定：细胞通过胰蛋白酶化采集，并与0.5 mg/mL RNase 和50 μg/mL碘化丙啶在室温下黑暗中进行培育；细胞活性通过流式细胞术使用FACScanto流式细胞分析仪分析，激发激光波长为488 nm，碘化丙啶荧光检测波长为600 nm。为测定细胞周期各阶段的细胞比例，细胞通过胰蛋白酶化采集，通过离心收集，用PBS洗涤，并在80%乙醇中于-20°C固定过夜。随后，将这些固定的细胞离心以除去固定剂，并于黑暗中，室温下，在包含0.5 mg/mL RNase 和50 μg/mL碘化丙啶的PBS中培养20分钟。流式细胞术分析如上进行。G1，S，和G2期的细胞比例使用MODFIT程序测定。细胞培养照片在指示时间使用结合具有20倍物镜的倒置显微镜的相机拍摄。 |
|||
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | pCofilin / Cofilin / detyrosinated alpha tubulin / acetylated alpha tubulin p-AMPK / AMPK / p-S6K / S6K / p-ACC |
|
26431377 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 | A-769662对正常Sprague Dawley大鼠的短期治疗降低肝脏丙二酰CoA水平，和换气比值，VCO2/VO2，表明整体脂肪酸氧化比率增加。A-769662(30 mg/kg, b.i.d.)治疗ob/ob小鼠，减少PEPCK，G6Pase，和FAS的肝脏表达，降低40%血浆葡萄糖，减少体重增加，并显著降低血浆和肝脏甘油三酯水平。[1] |
|
|---|---|---|
| 动物实验 | Animal Models | Sprague Dawley大鼠 |
| Dosages | 30 mg/kg | |
| Administration | 腹腔注射给药 | |
化学信息&溶解度
| 分子量 | 360.39 | 分子式 | C20H12N2O3S |
| CAS号 | 844499-71-4 | SDF | Download A-769662 SDF |
| Smiles | C1=CC=C(C(=C1)C2=CC=C(C=C2)C3=CSC4=C3C(=C(C(=O)N4)C#N)O)O | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 72 mg/mL ( (199.78 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy A-769662|A-769662 ic50|A-769662 price|A-769662 cost|A-769662 solubility dmso|A-769662 purchase|A-769662 manufacturer|A-769662 research buy|A-769662 order|A-769662 mouse|A-769662 chemical structure|A-769662 mw|A-769662 molecular weight|A-769662 datasheet|A-769662 supplier|A-769662 in vitro|A-769662 cell line|A-769662 concentration|A-769662 nmr|A-769662 in vivo|A-769662 clinical trial|A-769662 inhibitor|A-769662 PI3K/Akt/mTOR inhibitor
